EXAS
$103.94
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
Intraday
Recent News
1 Mid-Cap Stock to Consider Right Now and 2 Facing Headwinds
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Hedge Fund Beryl Capital Initiated a Position in CSG Systems Worth Over $54 Million. Is the Stock a Buy?
CSG Systems International delivers SaaS-based billing and customer engagement solutions to telecom and enterprise clients worldwide.
Exact Sciences Case Study Links Higher Screening Rates With Undervalued Shares
Exact Sciences has published a new case study on its collaboration with Amalgam Rx and Privia Health, focused on colorectal cancer screening. The program used EHR-integrated outreach and at-home noninvasive Cologuard tests to raise screening rates above national benchmarks. The initiative highlights a scalable approach to expanding access, supporting value-based care, and informing electronic quality measures. For investors watching Exact Sciences (NasdaqCM: EXAS), this case study...
3 Cash-Producing Stocks We Approach with Caution
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Cancer tests are becoming more precise and guiding pharma R&D
Abbott’s major takeover of Exact Sciences showcases a rising push to leverage cancer tests in precision oncology therapy and R&D.